Evidence map›Paper›PMID 40458922›Full record

ArticleCancer science2025

Genetic Profiling Reveals the Distinctions Among MTX-Associated DLBCL, EBV-Positive Mucocutaneous Ulcer, and EBV + DLBCL.

Takumi Takahashi, Keisuke Sawada, Takahisa Yamashita, Wataru Yamamoto, Yosuke Iijima, Akiko Adachi, Makoto Kashimura, Takayuki Tabayashi, Masahiro Kizaki, Takahiro Kaneko and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takumi TakahashiDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Keisuke SawadaDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Takahisa YamashitaDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Wataru YamamotoDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Yosuke IijimaDepartment of Oral and Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Akiko AdachiDepartment of Diagnostic Pathology, Saitama Red Cross Hospital, Saitama, Japan.
Makoto KashimuraDepartment of Hematology, Shinmatsudo Central General Hospital, Matsudo, Japan.
Takayuki TabayashiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Takahiro KanekoDepartment of Oral and Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Jun-Ichi TamaruDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Morihiro HigashiDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Shuji MomoseDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.ORCID https://orcid.org/0000-0003-3986-1409

Funding

50th Anniversary Research Grant 2Japan Society for the Promotion of Science 22K15413Japan Society for the Promotion of Science 23K15982Kamoda grant 04-F-1-11
6 · The paper itself

Abstract

The WHO recently changed the outline of immunodeficiency/dysregulation (IDD)-associated lymphoproliferative disorders (LPDs)/lymphomas from underlying IDD settings to an overarching framework and accommodates commonalities in histology, the involvement of various oncogenic viruses, and specific clinical/therapeutic consequences. A mutational analysis has been performed on post-transplantation and HIV-positive lymphomas, but not on other iatrogenic immunodeficiency (OII)-associated LPDs mainly caused by methotrexate (MTX) to treat rheumatoid arthritis. We herein conducted next-generation sequencing (NGS) to examine the genetic spectrum along with a fluorescence in situ hybridization analysis of 9p24.1 and PD-L1 expression in 37 MTX-associated diffuse large B-cell lymphoma (DLBCL) cases, 17 Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) cases, and 26 EBV-positive DLBCL (EBV + DLBCL) cases. Targeted NGS identified 177 mutations. The mutation frequency was significantly higher in EBV

Indexed as

Epstein-Barr Virus InfectionsLymphoma, Large B-Cell, DiffuseMethotrexateUlcerAdultAgedDioxygenasesDNA-Binding ProteinsFemaleHerpesvirus 4, HumanHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationDioxygenasesDNA-Binding ProteinsMethotrexateTET2 protein, human

Identifiers

PMID40458922
PMCPMC12317404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.